Healthy Annapolis

Final project for Urban Studies and Planning Studio (Summer 2017). University of Maryland, College Park.Annapolis, Maryland, located in Anne Arundel County, is home to the United States Naval Academy and Saint John’s College. The small waterfront capital city is also a popular tourist destination for sailors and history buffs drawn to the nationally recognized historic district. While continuing to focus on preserving the City’s historic and natural resources and strong local economy, Annapolis is taking steps to become a healthier city by participating in the Let’s Move! Cities Towns, and Counties (LMCTC) initiative, a national campaign to end childhood obesity by providing guidance to elected officials, parents, schools, community leaders, and other stakeholders in order to make healthy living accessible for everyone. Annapolis has successfully met the five initial program goals for LMCTC, and has achieved All-Star status. This report will help the City pursue three of the four All-Star strategies it is now eligible to pursue after achieving All-Star status. This report highlights disadvantaged communities, as they are more likely to suffer from poor health. In addition to an increased likelihood of health issues, these communities are also less likely to have resources such as education and community support to improve certain aspects of their health. This University of Maryland PALS summer studio project is meant to help guide the City of Annapolis in creating a healthier city for all residents, and in reaching their LMCTC All-Star strategies. Four chapters were written by groups that focused on health-related aspects of the city that relate directly to areas of focus for achieving All-Star status: 1) updates to incorporate health into the Comprehensive Plan, 2) parks and open space, 3) bicycle infrastructure, and 4) urban agriculture and community gardens. We hope that by providing recommendations for integrating health into the planning process and city design, and by suggesting strategies to make the most effective use of existing tools, Annapolis will be better situated to achieve its LMCTC All-Star strategies.The City of Annapoli

Simple PCR Assays Improve the Sensitivity of HIV-1 Subtype B Drug Resistance Testing and Allow Linking of Resistance Mutations

The success of antiretroviral therapy is known to be compromised by drug-resistant HIV-1 at frequencies detectable by conventional bulk sequencing. Currently, there is a need to assess the clinical consequences of low-frequency drug resistant variants occurring below the detection limit of conventional genotyping. Sensitive detection of drug-resistant subpopulations, however, requires simple and practical methods for routine testing.We developed highly-sensitive and simple real-time PCR assays for nine key drug resistance mutations and show that these tests overcome substantial sequence heterogeneity in HIV-1 clinical specimens. We specifically used early wildtype virus samples from the pre-antiretroviral drug era to measure background reactivity and were able to define highly-specific screening cut-offs that are up to 67-fold more sensitive than conventional genotyping. We also demonstrate that sequencing the mutation-specific PCR products provided a direct and novel strategy to further detect and link associated resistance mutations, allowing easy identification of multi-drug-resistant variants. Resistance mutation associations revealed in mutation-specific amplicon sequences were verified by clonal sequencing.Combined, sensitive real-time PCR testing and mutation-specific amplicon sequencing provides a powerful and simple approach that allows for improved detection and evaluation of HIV-1 drug resistance mutations

Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy

Using real-time PCR to detect HIV resistance mutations present at low levels, Jeffrey Johnson and colleagues investigate prevalence and clinical implications of minority transmitted mutations

International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined<5 × 10(-8)) and used pathway analysis to identify JAK-STAT/IL12/IL27 signalling and cytokine-cytokine pathways, for which relevant therapies exist